| Ytd | -76.25% | |
| 1y | -87.08% |
| Open | 0.77 | Prev Close | 0.78 | Low | 0.75 | High | 0.82 | Mkt Cap | 3.03M |
| Vol | 24.79K | Avg Vol | 39.50K | EPS | 4.60 | P/E | 0.17 | Forward P/E | -0.13 |
| Beta | -0.07 | Short Ratio | 0.11 | Inst. Own | 8.90% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 0.98 | 200-d Avg | 1.40 | 1yr Est | 12.75 |
REVB News
Gainers Werewolf Therapeutics (NASDAQ:HOWL) stock moved upwards by 77.1% to $0.76 during Thursday&#
– Study on track to begin later this year –Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Comp
Revelation Biosciences (NASDAQ:REVB) reported quarterly losses of $(0.87) per share which beat the a
The independent market assessment evaluated Gemini for the treatment of Stage 2 and Stage 3 Acute Ki
Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinic
https://s27.q4cdn.com/906368049/files/News/2026/Zacks_SCR_Research_05082026_REVB_Sorensen.pdf
Revelation Biosciences (NASDAQ:REVB) reported quarterly losses of $(2.71) per share which missed the
- A majority of CKD patients present with cellular inflammation and immunoparalysis predose --Gemini
Revelation Biosciences (NASDAQ:REVB) reported quarterly losses of $(1.65) per share which missed the
Revelation Biosciences, Inc. 4,272,500 Shares of Common Stock This prospectus relates to the resale,
https://s27.q4cdn.com/906368049/files/News/2026/Zacks_SCR_Research_01292026_REVB_Sorensen.pdf
Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), announce
Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinic
US stock futures slightly down after 2 days of gains. Trump withdraws tariffs on EU, while Q3 GDP ex
Revelation Biosciences shares jumped after the FDA agreed that a single Phase 2/3 study could suppor
Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinic
Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinic
Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinic
Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinic
Gemini normalized the inflammatory response at the cellular level in stage 3 and 4 CKD patients.Gemi
https://s27.q4cdn.com/906368049/files/News/2025/Zacks_SCR_Research_08082025_REVB_Sorensen.pdf
Revelation Biosciences (NASDAQ:REVB) reported quarterly losses of $(7.01) per share which missed the
https://endpoints.news/cder-director-tidmarsh-will-be-acting-head-of-fda-biologics-center-following-
U.S. futures rose on Wednesday after a mixed close on Tuesday. Futures of major benchmark indices we
